Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
335K
-
Shares change
-
-82.7K
-
Total reported value, excl. options
-
$837K
-
Value change
-
-$207K
-
Number of sells
-
-1
-
Price
-
$2.50
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2023
2 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2023.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 335K shares
of 193M outstanding shares and own 0.17% of the company stock.
Largest 10 shareholders include Whitefort Capital Management, LP (13.2M shares), BlackRock Inc. (10.4M shares), Two Seas Capital LP (9.04M shares), MORGAN STANLEY (6.98M shares), VANGUARD GROUP INC (5.99M shares), Woodline Partners LP (4.72M shares), Hudson Bay Capital Management LP (4.14M shares), ADAR1 Capital Management, LLC (3.47M shares), GEODE CAPITAL MANAGEMENT, LLC (2.82M shares), and STATE STREET CORP (2.4M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.